In terms of the appropriateness or status as experimental of Cisplatin/ VP16 for neuroendocrine carcinoma of the prostate, all neuroendocrine tumors that arise in other locations than lung, are gereally treated with the regimens used in the small cell cancer of the lung. The particular regimen used is a small cell lung cancer regimen. It is rare. There are no studies supporting this approach becaseu the subtype is rare; however, the approach used is generally within the consensus of medical oncologists.
Huang J, Yao JL, and di Sant’Agnese PA. Neuroendocrine Differentiation in Prostate Cancer. In: Prostate Cancer: Principles and Practice, edited by Roger Kirby, Alan Partin, Mark Feneley and J. Kellogg Parsons. Chapter 27, pp. 143-50. Taylor and Francis Medical Books, Abdington, UK (2006).
YASHI Masahiro et al, ll neuroendocrine carcinoma as a variant form of prostate cancer recurrence : A case report and short literature review Urologic oncology (Urol. oncol.) 2006, vol. 24, no4, pp. 313-317